About

Pergamum is a clinical-stage biopharmaceutical company with a particular focus on dermatology, wound healing and anti-infection.

Pergamum is building a new type of efficient biotech company and has recently merged and integrated three innovative biotech start-ups (DermaGen, PharmaSurgics and Lipopeptide) into one operational company.

The classical small biotech start-up model is often prone to failure. Many times this is the result of insufficient in-house drug/business development expertise. Even where such biotech companies survive, they invariably suffer from the time-consuming and costly restructuring processes needed to put the required expertise in place.

Within Pergamum, program management is de-centralized. Individual Operating Units ensure that entrepreneurial drive is maintained. Retaining these innovative units provides clearer focus and helps to minimize time-to-market for every product in the pipeline. It also provides an attractive form of diversification and overall risk spreading.

The Pergamum model and structure yields multiple competitive advantages:

• It provides leading-edge program management with efficient drug and business development to enable a higher success rate in drug development and minimize time-to-market.
• It captures synergies and enables cost savings.
• Entrepreneurial drive is maintained in the Operating Units, which remain focused on project milestones.
• It creates a cross-functional knowledge base.
• It provides appropriate risk management.
• It allows flexible exit and partnering opportunities.

Pergamum is already an attractive drug development "engine" for biotech and pharma companies. It will continue to attract, select and fully integrate the best early-stage programs, making sure they benefit from Pergamum's competitive advantages.